Astrazeneca Pharma India Ltd
₹
- close price
About
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]
Key Points
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of permanent employees (year-end) count ・Standalone data |
|
|||||||||
| CVRM (Cardiovascular + Diabetes) share of product sales % ・Standalone data |
||||||||||
| Oncology share of product sales % ・Standalone data |
||||||||||
| Respiratory (incl. Rare Disease) share of product sales % ・Standalone data |
||||||||||
| Oncology rank in IPM rank ・Standalone data |
||||||||||
| IPM overall rank (by revenue) rank ・Standalone data |
||||||||||
| Number of new regulatory approvals count ・Standalone data |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Communication To The Shareholders W.R.T. TDS On Dividend
1d - Shares TDS notice for final dividend ₹36/share; AGM August 10, record date July 31, 2026.
-
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
2d - Bhavana Agrawal resigns as CFO effective August 31, 2026, after moving to a regional AstraZeneca role.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Please find the enclosed intimation of the Company as per the captioned subject for your reference.
- Record Date For Payment Of Final Dividend 18 Jul
-
Business Responsibility and Sustainability Reporting (BRSR)
18 Jul - Filed FY2025-26 Business Responsibility and Sustainability Report with limited assurance by KPMG.
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
Concalls
-
Aug 2025TranscriptPPT
-
Aug 2024Transcript PPT
-
Aug 2023Transcript PPT
-
Aug 2022Transcript PPT
-
Aug 2021Transcript PPT
-
Sep 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptPPT
-
Dec 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
Sep 2018TranscriptAI SummaryPPT
Part of AstraZeneca UK plc
The company is promoted by AstraZeneca plc, a multinational pharmaceutical and biotechnology company headquartered in England. It has a diverse portfolio in various disease areas and has been successful in developing and manufacturing the Oxford-AstraZeneca COVID-19 vaccine. AstraZeneca Pharmaceuticals AB holds 75% of the company's shareholding.[1] [2]